1464 related articles for article (PubMed ID: 24865287)
1. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
Dudhipala N; Veerabrahma K
Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
[TBL] [Abstract][Full Text] [Related]
2. Formulation and Optimization of Candesartan Cilexetil Nano Lipid Carrier: In Vitro and In Vivo Evaluation.
Paudel A; Ameeduzzafar ; Imam SS; Fazil M; Khan S; Hafeez A; Ahmad FJ; Ali A
Curr Drug Deliv; 2017; 14(7):1005-1015. PubMed ID: 28034361
[TBL] [Abstract][Full Text] [Related]
3. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability.
Jain S; Reddy VA; Arora S; Patel K
Drug Deliv Transl Res; 2016 Oct; 6(5):498-510. PubMed ID: 27129488
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic studies of nisoldipine-loaded solid lipid nanoparticles developed by central composite design.
Dudhipala N; Veerabrahma K
Drug Dev Ind Pharm; 2015; 41(12):1968-77. PubMed ID: 25830370
[TBL] [Abstract][Full Text] [Related]
5. DEVELOPMENT OF SOLID LIPID NANOCARRIERS FOR ORAL DELIVERY OF CANDESERTAN CILEXETIL.
Ugurlu T; Nalbantoglu A; Sengel-Turk CT
Acta Pol Pharm; 2016 Nov; 73(6):1631-1638. PubMed ID: 29634119
[TBL] [Abstract][Full Text] [Related]
6. Role of Isradipine Loaded Solid Lipid Nanoparticles on the Pharmacodynamic Effect in Rats.
Thirupathi G; Swetha E; Narendar D
Drug Res (Stuttg); 2017 Mar; 67(3):163-169. PubMed ID: 27992936
[TBL] [Abstract][Full Text] [Related]
7. Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats.
Zhang Z; Gao F; Bu H; Xiao J; Li Y
Nanomedicine; 2012 Jul; 8(5):740-7. PubMed ID: 21930110
[TBL] [Abstract][Full Text] [Related]
8. Development and characterization of solid oral dosage form incorporating candesartan nanoparticles.
Nekkanti V; Pillai R; Venkateshwarlu V; Harisudhan T
Pharm Dev Technol; 2009; 14(3):290-8. PubMed ID: 19235553
[TBL] [Abstract][Full Text] [Related]
9. Improved anti-hyperlipidemic activity of Rosuvastatin Calcium via lipid nanoparticles: Pharmacokinetic and pharmacodynamic evaluation.
Dudhipala N; Veerabrahma K
Eur J Pharm Biopharm; 2017 Jan; 110():47-57. PubMed ID: 27810472
[TBL] [Abstract][Full Text] [Related]
10. Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles.
Vivek K; Reddy H; Murthy RS
AAPS PharmSciTech; 2007 Oct; 8(4):E83. PubMed ID: 18181544
[TBL] [Abstract][Full Text] [Related]
11. Candesartan cilexetil loaded nanodelivery systems for improved oral bioavailability.
Dudhipala N; Veerabrahma K
Ther Deliv; 2017 Feb; 8(2):79-88. PubMed ID: 28088883
[TBL] [Abstract][Full Text] [Related]
12. Three dimensional macroporous hydroxyapatite/chitosan foam-supported polymer micelles for enhanced oral delivery of poorly soluble drugs.
Zhang Y; Dong K; Wang F; Wang H; Wang J; Jiang Z; Diao S
Colloids Surf B Biointerfaces; 2018 Oct; 170():497-504. PubMed ID: 29960950
[TBL] [Abstract][Full Text] [Related]
13. Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics.
Kumar VV; Chandrasekar D; Ramakrishna S; Kishan V; Rao YM; Diwan PV
Int J Pharm; 2007 Apr; 335(1-2):167-175. PubMed ID: 17161566
[TBL] [Abstract][Full Text] [Related]
14. Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes.
Yan YD; Sung JH; Kim KK; Kim DW; Kim JO; Lee BJ; Yong CS; Choi HG
Int J Pharm; 2012 Jan; 422(1-2):202-10. PubMed ID: 22085435
[TBL] [Abstract][Full Text] [Related]
15. Development and in vitro/in vivo performance of self-nanoemulsifying drug delivery systems loaded with candesartan cilexetil.
AboulFotouh K; Allam AA; El-Badry M; El-Sayed AM
Eur J Pharm Sci; 2017 Nov; 109():503-513. PubMed ID: 28889028
[TBL] [Abstract][Full Text] [Related]
16. Development and characterization of mixed niosomes for oral delivery using candesartan cilexetil as a model poorly water-soluble drug.
Sezgin-Bayindir Z; Antep MN; Yuksel N
AAPS PharmSciTech; 2015 Feb; 16(1):108-17. PubMed ID: 25204859
[TBL] [Abstract][Full Text] [Related]
17. Effect of lipid matrix on repaglinide-loaded solid lipid nanoparticles for oral delivery.
Rawat MK; Jain A; Mishra A; Muthu MS; Singh S
Ther Deliv; 2010 Jul; 1(1):63-73. PubMed ID: 22816120
[TBL] [Abstract][Full Text] [Related]
18. Lipid nanoparticles of zaleplon for improved oral delivery by Box-Behnken design: optimization, in vitro and in vivo evaluation.
Dudhipala N; Janga KY
Drug Dev Ind Pharm; 2017 Jul; 43(7):1205-1214. PubMed ID: 28274147
[TBL] [Abstract][Full Text] [Related]
19. New supersaturating drug delivery system as strategy to improve apparent solubility of candesartan cilexetil in biorelevant medium.
Pinto JMO; Leão AF; Alves GF; Mendes C; França MT; Fernandes D; Stulzer HK
Pharm Dev Technol; 2020 Jan; 25(1):89-99. PubMed ID: 31583925
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of solubility and permeability of Candesartan cilexetil by using different pharmaceutical interventions.
Shaikh SM; Avachat AM
Curr Drug Deliv; 2011 Jul; 8(4):346-53. PubMed ID: 21453263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
